Thanks I can see how this is a smarter risk / reward vs ANIP. Almost impossible to really “price” or value Ani. Generics business is endless competition, branded business is tailing off and needs néw blood, Cort is a total guess on success or numbers. That being said, ani is holding high 20’s - oddly. Regards